Teva Pharmaceutical Industries LTD Form 4 insider transactions

Tal Zvi Zaks, a Director of Teva Pharmaceutical Industries Ltd, sold 17 shares of common stock on August 5, 2026 for $34.87 per share.

Teva Pharmaceutical Industries Ltd. CFO Eliyahu Sharon Kalif sold a portion of his holdings in ordinary shares as part of a pre-arranged trading plan.

Teva Pharmaceuticals Director Sol J. Barer reported a transaction involving ordinary shares and restricted share units on June 5, 2026.

Chen Lichtenstein, a Director at Teva Pharmaceutical Industries Ltd., reported transactions involving ordinary shares and restricted share units.

Rosemary A. Crane, a Director at TEVA Pharmaceutical Industries Ltd., reported transactions involving ordinary shares and restricted share units.

Teva Pharmaceutical Industries Ltd. director Amir Elstein has reported the acquisition of 14,492 ordinary shares through restricted share units that vested on June 5, 2026.

Teva Pharmaceutical Industries Ltd. director Perry Nisen has reported the acquisition of 14,492 ordinary shares through the vesting of restricted share units.

Teva Pharmaceutical Industries Ltd. Director Ronit Satchi-Fainaro has reported transactions involving ordinary shares and restricted share units.

Teva Pharmaceuticals Director Tal Zvi Zaks acquired 14,492 ordinary shares through the vesting of restricted share units.

Director Roberto Mignone reported a transaction involving Teva Pharmaceutical Industries Ltd. ordinary shares, acquiring restricted share units and disposing of some shares.

Teva Pharmaceuticals President and CEO Richard D. Francis reported transactions involving ordinary shares and restricted share units, including sales to cover tax obligations.

Teva Pharmaceutical Industries Ltd. executive Matthew Shields reported a transaction involving the sale of ordinary shares acquired through restricted share units under a pre-arranged 10b5-1 trading plan.

Teva Pharmaceuticals Director Tal Zvi Zaks acquired 7,242 restricted share units on May 28, 2026, as part of a compensation plan.

Teva Pharmaceuticals Director Perry Nisen acquired 7,242 restricted share units on May 28, 2026, as part of his compensation.

Gerald M. Lieberman, a Director at Teva Pharmaceutical Industries Ltd., acquired 7,242 restricted share units.

Teva Pharmaceuticals Director Amir Elstein acquired 7,242 restricted share units on May 28, 2026, as disclosed in a Form 4 filing.

Rosemary A. Crane, a Director at Teva Pharmaceutical Industries Ltd., has acquired 7,242 restricted share units, as disclosed in a recent SEC Form 4 filing.

Teva Pharmaceuticals Director Sol J. Barer acquired 10,863 restricted share units on May 28, 2026, as disclosed in a Form 4 filing.

Roberto Mignone, a Director at Teva Pharmaceutical Industries Ltd., acquired 7,242 restricted share units on May 28, 2026, as part of his compensation.

Teva Pharmaceutical Industries Ltd. executive Evan Lippman reported transactions involving ordinary shares and restricted share units under a pre-arranged trading plan.

Teva Pharmaceutical Industries Ltd. CFO Eliyahu Sharon Kalif sold a significant number of ordinary shares under a pre-arranged trading plan.

Teva Pharmaceutical Industries Ltd. executive Mark Sabag reported the sale of 80,760 ordinary shares.

Christine Fox, EVP of U.S. Commercial at Teva Pharmaceutical Industries Ltd., reported the sale of 21,258 ordinary shares.

Mark Sabag, Teva Pharmaceutical's EVP of International Markets Commercial, sold 62,102 ordinary shares for approximately $30.14 per share.

Teva Pharmaceutical Industries CEO Richard D. Francis reported the vesting and sale of ordinary shares, alongside the grant of new restricted share units.

Richard Daniell, Teva Pharmaceutical Industries' EVP of Europe Commercial, sold ordinary shares totaling 91,345 units following the vesting of restricted share units, executed under a pre-arranged 10b5-1 trading plan.

Teva Pharmaceutical Industries Ltd. granted its Executive Vice President, Chief Human Resources Officer, Placid Jover, 37,982 restricted share units vesting over four years.

Teva Pharmaceutical Industries Ltd.'s EVP of Global Operations, Matthew Shields, was granted 33,424 restricted share units with a multi-year vesting schedule.

Teva Pharmaceutical Industries Ltd. Executive Vice President Mark Sabag reported the vesting and acquisition of ordinary shares from restricted share units as part of his compensation.

Teva Pharmaceutical Industries Ltd. granted its EVP of Business Development, Evan Lippman, 27,347 restricted share units as part of a Rule 10b5-1 plan.